CALGARY, Alberta and VANCOUVER, British Columbia--(BUSINESS WIRE)--The Centre for Drug Research and Development (CDRD) announced today the signing of affiliation agreements with both the University of Calgary and University Technologies International (UTI). CDRD’s mission is to bridge the commercialization gap between drug discovery and private investment by providing resources to translate academic discoveries into new medicines. As such, these agreements will provide University of Calgary and UTI investigators with access to CDRD’s infrastructure and expertise to assist them in overcoming scientific and project management challenges faced as they work to develop new therapeutics for the treatment of human disease.
“We are pleased to reach this agreement with CDRD, as it will give our medical research community added external support as they look at developing a wide array of innovative medical solutions,” said Dr. Jon Meddings, Interim Vice President of Research at the University of Calgary.
“Leveraging CDRD’s expertise augments the strategic partnerships necessary for the development of promising drug candidates and their translation into potential cures or treatments for patients,” states David Reese, Acting Director, Licensing and Business Development, University Technologies International.
“By working with the leading researchers at the University of Calgary and the commercialization office of UTI, we believe that CDRD’s full drug development platform can be effectively utilized to help accelerate and advance the development of their discoveries, taking them one step closer to becoming innovative medical therapeutics,” said Karimah Es Sabar, Senior Vice President, Business & Strategic Affairs at CDRD.
About the University of Calgary
The University of Calgary is a comprehensive research university that is ranked top 10 in Canada for research income, fundraising, endowment, research competitions and national awards. The University of Calgary has 1,800 academic staff actively engaged in research, scholarship and teaching in Canada and around the world, and more than 2,900 staff, making it one of the largest employers in Calgary. The university produces an economic impact of $1 billion in the Calgary area alone. High-priority areas of research include energy and the environment, biomedical engineering and public policy. Multidisciplinary research is core to the university’s teaching and research mandate. For more information, visit: www.ucalgary.ca.
About University Technologies International
UTI is the University of Calgary’s technology transfer, commercialization and incubation center servicing the Calgary region. UTI was founded in 1989 and consistently ranks in the top 4 centers of its kind in Canada and is recognized as an innovation leader in commercializing technology. IGNITE, launched in early 2007, is a company creation incubator designed at UTI to develop investment grade companies. IGNITE creates companies where intellectual property and proprietary technology provides a sustainable, differentiated, competitive advantage. UTI and IGNITE provide economic development to the Calgary region through the creation of new jobs, the sharing of knowledge, the pooling of resources and the opportunity for investment return. For more information visit: www.uti.ca.
The Centre for Drug Research and Development (CDRD) (www.cdrd.ca) provides drug development expertise and infrastructure to enable researchers from leading academic and health research institutions to advance promising, early-stage drug candidates. CDRD combines its drug development platform with a commercial arm, which licenses technologies from affiliated institutions and establishes working collaborations with other biotech and lifesciences companies. The Government of Canada's Networks of Centres of Excellence program has recognized CDRD as a Centre of Excellence in Commercialization in Research (CECR).
Researchers at the University of Calgary are encouraged to contact John Coleman, Head, CDRD’s Project Search team (email@example.com) to learn more about collaborations with CDRD.